Search research articles
Contact Us
Filters
Showing results (231-240 of 258) with videos related to
Page
of 26
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 27, 2017
Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab
D Arnold, C S Fuchs, J Tabernero, et al.
Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia
|
August 5, 2021
Overview of virus and cancer relationships. Position paper
E Bouza, M Martín Jiménez, L Alemany, et al.
British Journal of Cancer
|
May 14, 2008
Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer
L Paz-Ares, H Ross, M O'Brien, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 30, 2010
Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM)
R Colomer, E Alba, A González-Martin, et al.
ESMO Open
|
March 13, 2022
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN
L Paz-Ares, Y Chen, N Reinmuth, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 21, 2017
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
L Paz-Ares, E-H Tan, K O'Byrne, et al.
ESMO Open
|
November 21, 2023
Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial
H Borghaei, K J O'Byrne, L Paz-Ares, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2000
Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group
J Bellmunt, V Guillem, L Paz-Ares, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 27, 2020
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial
L Paz-Ares, A Spira, D Raben, et al.
British Journal of Cancer
|
April 12, 2012
First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours
T A Yap, H Cortes-Funes, H Shaw, et al.
Page
of 26
Search research articles
Search
Showing results (231-240 of 258) with videos related to
Sort By:
Page
of 26
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 27, 2017
Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab
D Arnold, C S Fuchs, J Tabernero, et al.
Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia
|
August 5, 2021
Overview of virus and cancer relationships. Position paper
E Bouza, M Martín Jiménez, L Alemany, et al.
British Journal of Cancer
|
May 14, 2008
Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer
L Paz-Ares, H Ross, M O'Brien, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 30, 2010
Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM)
R Colomer, E Alba, A González-Martin, et al.
ESMO Open
|
March 13, 2022
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN
L Paz-Ares, Y Chen, N Reinmuth, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 21, 2017
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
L Paz-Ares, E-H Tan, K O'Byrne, et al.
ESMO Open
|
November 21, 2023
Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial
H Borghaei, K J O'Byrne, L Paz-Ares, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2000
Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group
J Bellmunt, V Guillem, L Paz-Ares, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 27, 2020
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial
L Paz-Ares, A Spira, D Raben, et al.
British Journal of Cancer
|
April 12, 2012
First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours
T A Yap, H Cortes-Funes, H Shaw, et al.
Page
of 26